Skip to main content

Advertisement

Table 2 Calculated values for the Combination Index as a growth inhibitory effect of combination treatment with Herceptin® and Doxorubicin in gastric cancer cell lines

From: Correlation between HER-2/neu(erbB-2) expression level and therapeutic effect of combination treatment with HERCEPTIN and chemotherapeutic agents in gastric cancer cell lines

YBC-2 Combination Index Value Parameter (μM)
Drug ED50 ED75 ED90 Dm m r
DOX     2.93 0.54 0.98
HER     1201.02 0.32 0.91
DOX + HER 0.09 0.05 0.03 0.25 0.74 0.96
Diagnosis combined effect synergy synergy synergy    
YBC-3 Combination Index Value Parameter (μM)
Drug ED50 ED75 ED90 Dm m r
DOX     2.310 0.768 0.946
HER     46.063 0.623 0.970
DOX + HER 0.266 0.598 1.377 0.406 0.469 0.925
Diagnosis combined effect synergy synergy antagonism    
NCI-N87 Combination Index Value Parameter (μM)
Drug ED50 ED75 ED90 Dm m r
DOX     0.070 0.398 0.864
HER     113350 0.191 0.635
DOX + HER 0.005 0.004 0.003 0.000 0.437 0.995
Diagnosis combined effect synergy synergy synergy    
U-87 MG Combination Index Value Parameter (μM)
Drug ED50 ED75 ED90 Dm m r
DOX     0.295 0.620 0.997
HER     1845.5 0.457 0.860
DOX + HER 0.441 0.435 0.448 0.101 0.589 0.992
Diagnosis combined effect synergy synergy synergy    
SK-BR-3 Combination Index Value Parameter (μM)
Drug ED50 ED75 ED90 Dm m r
DOX     0.103 0.832 0.998
HER     1424000 0.046 0.435
DOX + HER 0.046 0.074 0.117 0.005 0.616 0.985
Diagnosis combined effect synergy synergy synergy    
  1. DOX, Doxorubicin; HER, Herceptin.